CoChat

Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial

Open access
Costi, Sara, Morris, Laurel S., Kirkwood, Katherine A., Hoch, Megan, Corniquel, Morgan, Vo-Le, Brittany, Iqbal, Tabish, Chadha, Nisha, Pizzagalli, Diego A., Whitton, Alexis, Bevilacqua, Laura, Jha, Manish K., Ursu, Stefan, Swann, Alan C., Collins, Katherine A., Salas, Ramiro, Bagiella, Emilia, Parides, Michael K., Stern, Emily R., Iosifescu, Dan V., Han, Ming-Hu, Mathew, Sanjay J., Murrough, James W. · 2021 · American Journal of Psychiatry
Cited by 78

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Preclinical studies point to the KCNQ2/3 potassium channel as a novel target for the treatment of depression and anhedonia, a reduced ability to experience pleasure. The authors conducted the first randomized placebo-controlled trial testing the effect of the KCNQ2/3 positive modulator ezogabine on reward circuit activity and clinical outcomes in patients with depression. METHODS: Depressed individuals (N=45) with elevated levels of anhedonia were assigned to a 5-week treatment period with ezogabine (900 mg/day; N=21) or placebo (N=24). Participants underwent functional MRI during a reward flanker task at baseline and following treatment. Clinical measures of depression and anhedonia were collected at weekly visits. The primary endpoint was the change from baseline to week 5 in ventral striatum activation during reward anticipation. Secondary endpoints included depression and anhedonia severity as measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Snaith-Hamilton Pleasure Scale (SHAPS), respectively. RESULTS: The study did not meet its primary neuroimaging endpoint. Participants in the ezogabine group showed a numerical increase in ventral striatum response to reward anticipation following treatment compared with participants in the placebo group from baseline to week 5. Compared with placebo, ezogabine was associated with a significantly larger improvement in MADRS and SHAPS scores and other clinical endpoints. Ezogabine was well tolerated, and no serious adverse events occurred. CONCLUSIONS: The study did not meet its primary neuroimaging endpoint, although the effect of treatment was significant on several secondary clinical endpoints. In aggregate, the findings may suggest that future studies of the KCNQ2/3 channel as a novel treatment target for depression and anhedonia are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2020.20050653

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

Metadata

Authors
Costi, S., Morris, L. S., Kirkwood, K. A., Hoch, M., Corniquel, M., Vo-Le, B., Iqbal, T., Chadha, N., Pizzagalli, D. A., Whitton, A., Bevilacqua, L., Jha, M. K., Ursu, S., Swann, A. C., Collins, K. A., Salas, R., Bagiella, E., Parides, M. K., Stern, E. R., Iosifescu, D. V., Han, M.-H., Mathew, S. J., & Murrough, J. W.
Venue
American Journal of Psychiatry
Published
2021-05-01
Volume
178
Issue
5
Pages
437-446
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W3133877026
Cited by
78
References
24
FWCI
5.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.